Intrigue builds as Novo goes public with higher Metsera bid

Five weeks after it appeared that Pfizer was getting back into the obesity race via its acquisition of Metsera for up to $7.3 billion, those ambitions could be curtailed by an unsolicited bid from Novo Nordisk, which is offering $8.5 billion to acquire Metsera. 

For Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO), the public disclosure of the offer is the culmination of a year-long pursuit of Metsera amid the obesity giant’s falling market share to rival Eli Lilly and Co. (NYSE:LLY), and raises questions about the level of confidence the Danish biopharma has in the commercial potential of its next major obesity product, CagriSema. ...